Vectura names Will Downie as CEO and Executive Director

Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in various roles at GE Healthcare, Amersham Health, and Quintiles.

In July 2019, Vectura announced that it would focus its R&D efforts on development of its inhaled drug candidates and that it would begin “offering development services where a smaller proportion of the overall contract value is delivered through contingent milestones.”

Vectura Chairman Bruno Angelici said, “I am very pleased to welcome Will Downie as Vectura’s new CEO. He brings a wealth of relevant experience which will help Vectura to grow and deliver on its new strategic focus as a leading inhaled CDMO business. I would like to thank Paul Fry for the significant work he has done since stepping into the Interim Chief Executive role and driving the change necessary for Vectura to become a leading player in the inhaled CDMO space. Paul will resume his responsibilities as Chief Financial Officer from 7^th November.”

Downie commented, “I am delighted to have accepted the role of CEO of Vectura and to have the opportunity to expand and build on its reputation as an inhalation device and formulation specialist. I am looking forward to driving the new business strategy and ensuring the company achieves its long-term goal of becoming a world-class CDMO organization in the inhalation space.”

Read the Vectura press release.